论文部分内容阅读
为探讨乳腺癌Ｐ６２ｃ－ｍｙｃ蛋白在乳腺癌中的表达及其临床意义，采用ＬＳＡＢ免疫组化法对１０７例乳腺癌标本进行Ｐ６２ｃ－ｍｙｃ蛋白的检测。结果显示：Ｐ６２ｃ－ｍｙｃ蛋白表达阳性率为６３．５５％（６８／１０７），对生存时间≤５年、＞５年～＜１０年和≥１０年者，其Ｐ６２ｃ－ｍｙｃ蛋白表达阳性率分别为９４．００％（４７／５０），６５．００％（１３／２０）和２１．６２％（８／３７）；Ｐ６２ｃ－ｍｙｃ蛋白过度表达与乳腺癌的临床分期，组织学分级，腋淋巴结转移有关，由此提示Ｐ６２ｃ－ｍｙｃ蛋白表达是判断乳腺癌预后的一个重要指标。
To investigate the expression and clinical significance of P62c-myc protein in breast cancer, LSAB immunohistochemistry was used to detect P62c-myc protein in 107 breast cancer specimens. The results showed that the positive rate of P62c-myc protein expression was 63.55% (68/107). The positive rates of P62c-myc protein expression were positive for those with survival time ≤ 5 years, >5 years to <10 years and ≥10 years. 94.00% (47/50), 65.00% (13/20) and 21.62% (8/37); P62c-myc protein overexpression and clinical staging of breast cancer, histological grade, axillary lymph node Metastasis is related, suggesting that P62c-myc protein expression is an important indicator of the prognosis of breast cancer.